Blood Cancer Clinical Trial Landscape: 2673 Active Trials, 683 Sponsors

2673

Active Trials

1449

Actively Recruiting

286

Phase 3 Active

683

Distinct Sponsors

Early Phase 1: 65 Phase 1: 872 Phase 2: 1236 Phase 3: 286 Phase 4: 29

The blood cancer trial landscape in 2026

"Blood cancer" covers three broad lineages: the leukemias (acute and chronic, myeloid and lymphoid), the lymphomas (Hodgkin and non-Hodgkin), and plasma-cell and myeloid neoplasms (multiple myeloma, MDS, myelofibrosis). These are the leading edge of cell and immune therapy — CAR-T, bispecific antibodies, and targeted small molecules — and many programs move across several subtypes at once. A complete hematologic view tracks the major lineages and the high-volume subtypes together.

Active blood cancer trials by subtype

Categories overlap (leukemia includes AML/ALL/CLL; the lymphoma total is the full lymphoma hub), so the rows below do not sum to the total above. Each links to a dedicated landscape page.

Major categories

Subtype	Active	Recruiting	Phase 3
Leukemia (all types)	1157	646	101
Lymphoma (all types)	1233	662	126
Multiple Myeloma	564	284	77
Myelodysplastic Syndromes (MDS)	275	155	14
Myelofibrosis	90	50	10

Leukemia subtypes

Subtype	Active	Recruiting	Phase 3
Acute Myeloid Leukemia (AML)	450	262	28
Acute Lymphoblastic Leukemia (ALL)	272	160	22
Chronic Lymphocytic Leukemia (CLL)	219	104	33

Track every new blood cancer trial automatically

ClinicalTrials.gov updates daily. Our pipeline monitors it for you and delivers a clean digest every morning.

Get Free Alerts — No Credit Card

Most active industry sponsors

Largest industry-sponsored blood cancer trial portfolios by active study count:

Sponsor	Active Trials
Johnson & Johnson / Janssen	51
Bristol-Myers Squibb	33
AstraZeneca	31
Roche / Genentech	29
AbbVie	29

What we monitor

Our pipeline pulls from ClinicalTrials.gov every day. For a blood cancer watch profile, alerts can be configured for:

New study registrations and status changes (e.g. opened to recruiting, completed)
Protocol changes — enrollment, endpoints, phase, and completion-date movements
New sponsor entrants into a subtype
Phase filters (Phase 1 for novel mechanisms, Phase 3 for registration programs)
Sponsor-type filters (large pharma vs. emerging biotech vs. academic)

Ready to automate your blood cancer trial monitoring?

Free plan — no credit card required. Set up your profile in 2 minutes.

Start Free

Frequently asked questions

How many blood cancer clinical trials are actively recruiting?

1449 blood cancer (hematologic malignancy) trials are actively recruiting on ClinicalTrials.gov, out of 2673 active studies overall, including 286 in Phase 3. Counts on this page regenerate from ClinicalTrials.gov on every update.

Which blood cancers does this cover?

The leukemias (AML, ALL, CLL, and others), the lymphomas (Hodgkin and non-Hodgkin), multiple myeloma, myelodysplastic syndromes (MDS), and myelofibrosis. Each category above links to its own landscape page.

Can I track just one blood cancer subtype?

Yes. Every subtype above has a dedicated page, and in the dashboard you can scope a watchlist to a single disease (for example AML or multiple myeloma) and receive a separate daily digest.

Pricing

Free — $0 forever: 1 disease tracker, weekly digest, ClinicalTrials.gov monitoring. No credit card required.

Starter — $49/month: 5 disease/keyword profiles, daily digest, all phase and sponsor filters. Best for individual analysts.

Pro — $149/month: Unlimited profiles, daily digest, priority support. Best for BD and CI teams.

Last updated: 2026-06-14 · Data from ClinicalTrials.gov · View full pipeline →

Blood Cancer Clinical Trial Landscape